FDA “Progressive Approval” And “Exceptional Approval” Pathways Possible Under Senate Bill
This article was originally published in The Pink Sheet Daily
Executive Summary
Legislation being drafted by Sen. Kay Hagan, D-N.C., would formalize FDA practices of approving drugs in certain circumstances where the evidence needed for a standard approval cannot be generated.